BEXIMCO PHARMA.GDR REGS 1 (F:R2WA) — Market Cap & Net Worth
Market Cap & Net Worth: BEXIMCO PHARMA.GDR REGS 1 (R2WA)
BEXIMCO PHARMA.GDR REGS 1 (F:R2WA) has a market capitalization of $208.62 Million (€178.44 Million) as of September 17, 2026. Listed on the F stock exchange, this Germany-based company holds position #16467 globally and #1554 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BEXIMCO PHARMA.GDR REGS 1's stock price €0.40 by its total outstanding shares 446112089 (446.11 Million). Also see BEXIMCO PHARMA.GDR REGS 1 (R2WA) total assets for a full breakdown of the balance sheet.
BEXIMCO PHARMA.GDR REGS 1 Market Cap History: 2015 to 2026
BEXIMCO PHARMA.GDR REGS 1's market capitalization history from 2015 to 2026. Data shows growth from $93.04 Million to $208.62 Million (10.13% CAGR). Also see R2WA cash generation efficiency for how efficiently the company converts equity into cash flow.
BEXIMCO PHARMA.GDR REGS 1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BEXIMCO PHARMA.GDR REGS 1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest BEXIMCO PHARMA.GDR REGS 1 stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
BEXIMCO PHARMA.GDR REGS 1's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.04x
BEXIMCO PHARMA.GDR REGS 1's market cap is 0.04 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $522.60 Million | $29.49 Billion | $5.13 Billion | 0.02x | 0.10x |
| 2022 | $259.89 Million | $34.67 Billion | $5.12 Billion | 0.01x | 0.05x |
| 2023 | $208.15 Million | $39.27 Billion | $4.61 Billion | 0.01x | 0.05x |
| 2024 | $215.92 Million | $44.39 Billion | $5.83 Billion | 0.00x | 0.04x |
Competitor Companies of R2WA by Market Capitalization
Companies near BEXIMCO PHARMA.GDR REGS 1 in the global market cap rankings as of September 17, 2026. Review how tangible is BEXIMCO PHARMA.GDR REGS 1's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to BEXIMCO PHARMA.GDR REGS 1 by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
BEXIMCO PHARMA.GDR REGS 1 Historical Marketcap From 2015 to 2026
Between 2015 and today, BEXIMCO PHARMA.GDR REGS 1's market cap moved from $93.04 Million to $ 208.62 Million, with a yearly change of 10.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €208.62 Million | 0.00% |
| 2025 | €208.62 Million | -3.38% |
| 2024 | €215.92 Million | +3.73% |
| 2023 | €208.15 Million | -19.91% |
| 2022 | €259.89 Million | -50.27% |
| 2021 | €522.60 Million | +22.85% |
| 2020 | €425.38 Million | +124.31% |
| 2019 | €189.64 Million | +12.26% |
| 2018 | €168.93 Million | -22.31% |
| 2017 | €217.43 Million | +7.67% |
| 2016 | €201.94 Million | +117.04% |
| 2015 | €93.04 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of BEXIMCO PHARMA.GDR REGS 1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $208.62 Million USD |
| MoneyControl | $208.62 Million USD |
| MarketWatch | $208.62 Million USD |
| marketcap.company | $208.62 Million USD |
| Reuters | $208.62 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BEXIMCO PHARMA.GDR REGS 1
Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskelet… Read more